CENTOGENE Reviews Third-Quarter 2020 Economical Success and Will increase Entire Calendar year Advice

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (Globe NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-phase company focused on rare conditions that transforms serious-environment medical and genetic info into actionable details for sufferers, doctors, and pharmaceutical corporations, these days offered an update on its corporate progress and noted its monetary results for the 3 and 9 months ended September 30, 2020.

• Revenues greater 212% when compared to Q3 2019, pushed by the ongoing growth of our COVID-19 tests offering
• Greater 2020 entire-yr revenue guidance to extra than €100 million
• Ongoing growth of new pharma partnerships, with 12 new promotions signed and a sturdy recovery anticipated in 2021
• Growth of industrial COVID-19 testing, which now contains antigen screening
• Introduced management changeover and appointment of Dr. Andrin Oswald as Chief Government Officer to aid the up coming phase of the Company’s growth

Andrin Oswald, M.D., Main Government Officer at CENTOGENE, reported, “I am psyched to have joined CENTOGENE at such an important phase in the Company’s evolution. When I have only been with CENTOGENE for a several weeks, it is very clear to me that our overall group is targeted on acquiring a popular intention of helping scarce illness people about the world. We believe that that our mission has the opportunity to significantly decrease the burden of uncommon health conditions – and offers an remarkable value development prospect for our stakeholders at the exact time. Leveraging extra than 20 several years of expert knowledge throughout the daily life sciences, together with my time at Novartis and the Invoice and Melinda Gates Foundation, I am seeking ahead to assisting additional scale and accelerate CENTOGENE’s growth as a chief in the unusual disorder space.”

Richard Stoffelen, Main Financial Officer at CENTOGENE, said, “During the 3rd quarter, we observed a sizeable maximize in our revenues, year-about-calendar year, driven by our means to leverage our main competency in specific health care diagnoses to pivot swiftly and provide solutions to help handle the COVID-19 pandemic. As we tactic the stop of what has been an unparalleled 12 months, I would like to thank the whole CENTOGENE staff once a lot more for their adaptability and unwavering commitment.”

A Solid Basis for 2021

CENTOGENE has leveraged its main competency of providing specific health care diagnoses, as very well as its infrastructure, to aid prevent even more outbreaks of SARS-CoV-2 (COVID-19) through 2020. As part of this initiative, CENTOGENE has come to be 1 of the biggest COVID-tests businesses in Europe and developed a pioneering and foremost function in giving tests services at airports. The beneficial monetary contribution from COVID-19 tests will enable the Firm to make strategic investments to even further solidify its foremost position in the exceptional sickness house. The amount of Pharma partnership discussions have also ongoing to improve given that Q2 2020, positioning CENTOGENE for even more progress in 2021.

Even further information on the Company’s Q3 2020 Earnings, which include the management’s dialogue and analysis of financial issue and benefits of functions, can be discovered by viewing EDGAR on the SEC web site at www.sec.gov, as well as the Investor Relations webpage of the Company’s web page at http://buyers.centogene.com.

About CENTOGENE

CENTOGENE engages in diagnosis and exploration about exceptional conditions reworking genuine-planet scientific and genetic facts into actionable info for sufferers, doctors, and pharmaceutical firms. Our goal is to provide rationality to remedy conclusions and to speed up the improvement of new orphan medicine by making use of our extensive scarce sickness understanding, which includes epidemiological and clinical knowledge, as perfectly as impressive biomarkers. CENTOGENE has developed a world proprietary unusual disease platform centered on our authentic-globe knowledge repository with about 3.6 billion weighted details details from approximately 595,000 patients representing more than 120 different international locations as of September 30, 2020.

The Company’s platform includes epidemiologic, phenotypic, and genetic data that displays a world inhabitants, and also a biobank of these patients’ blood samples. CENTOGENE believes this signifies the only platform that comprehensively analyzes multi-level info to improve the being familiar with of scarce hereditary conditions, which can assist in the identification of patients and enhance our pharmaceutical partners’ skill to deliver orphan medicine to the sector. As of September 30, 2020, the Organization collaborated with around 40 pharmaceutical associates covering about 45 distinct rare illnesses.

Significant See and Disclaimer

This push launch incorporates statements that constitute “forward-wanting statements” as that phrase is defined in the United States Personal Securities Litigation Reform Act of 1995, which include statements that specific the Company’s viewpoints, expectations, beliefs, options, targets, assumptions, or projections regarding long term situations or long run benefits, in distinction with statements that replicate historical specifics. Illustrations involve dialogue of our procedures, financing ideas, progress opportunities, and sector progress. In some scenarios, you can determine these forward-seeking statements by terminology these as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could,” or “should,” the detrimental of these phrases or identical expressions. Forward-seeking statements are based on management’s recent beliefs and assumptions and on info now obtainable to the Organization. Nonetheless, these ahead-searching statements are not a warranty of our performance, and you need to not position undue reliance on these types of statements. Ahead-looking statements are subject to numerous risks, uncertainties, and other variable instances, these kinds of as adverse around the globe financial circumstances and ongoing instability and volatility in the all over the world fiscal markets, the outcomes of the COVID-19 pandemic on our enterprise and final results of functions, doable alterations in present-day and proposed legislation, polices and govern-mental policies, pressures from growing level of competition and consolidation in our industry, the expense and uncertainty of regulatory acceptance, such as from the U.S. Meals and Drug Administration, our reliance on third events and collaboration partners, together with our capacity to manage advancement and enter into new shopper relationships, our dependency on the uncommon disorder market, our potential to manage intercontinental growth, our reliance on vital personnel, our reliance on intellectual assets protection, fluctuations of our operating outcomes owing to the effect of trade charges, or other components. These dangers and uncertainties may well result in the statements to be inaccurate and readers are cautioned not to area undue reliance on this sort of statements. A lot of of these dangers are outside the house of the Company’s handle and could lead to its precise benefits to differ materially from those it assumed would arise. The forward-looking statements bundled in this press launch are manufactured only as of the day hereof. The Organization does not undertake, and especially declines, any obligation to update any these kinds of statements or to publicly announce the success of any revisions to any such statements to replicate upcoming activities or developments, besides as necessary by legislation.

For further data, make sure you refer to the Risk Things portion in our Yearly Report for the year finished December 31, 2019, on Kind 20-F submitted with the SEC on April 23, 2020, Variety 6-K made up of our money outcomes for the 3 months ended March 31, 2020, furnished to the SEC on June 15, 2020, Type 6-K containing our financial benefits for the a few and 9 months finished September 30, 2020, furnished to the SEC on December 16, 2020, and other current reviews and paperwork furnished to or filed with the U.S. Securities and Trade Commission (SEC). You could get these paperwork by traveling to EDGAR on the SEC internet site at www.sec.gov.

 

Media Get hold of: CENTOGENE Sunlight Kim Main Technique and Trader Relations Officer [email protected]     FTI Consulting Bridie Lawlor O’Boyle +1.917.929.5684 [email protected]